47results about How to "Reduce neuroinflammation" patented technology

Devices, systems and methods are disclosed for treating or preventing dementia, such as Alzheimer's disease. The methods comprise transmitting impulses of energy non-invasively to selected nerve fibers, particularly those in a vagus nerve, that modulate the activity of a patient's locus ceruleus. The transmitted energy impulses, comprising magnetic and/or electrical energy, stimulate the selected nerve fibers to cause the locus ceruleus to release norepinephrine into regions of the brain that contain beta-amyloids. The norepinephrine counteracts neuroinflammation that would damage neurons in those regions and the locus ceruleus, thereby arresting or slowing the progression of the disease in the patient.

The present invention provides methods for treating subjects having or at risk of having a neuropathological disorder or brain inflammatory diseases with and without vascular involvement, and systemic inflammatory vascular disease by administering a therapeutically effective amount of Activated Protein C (APC) to the subject. Brain disorders and brain inflammatory vascular diseases that can be treated by the invention method include all neurodegenerative diseases with different types of neuronal dysfunction, including stroke, Alzheimer's disease, Parkinson's disease, Huntington disease, neuroimmunological disorders such as multiple scelrosis and Gullian-Barre, encephalitis, meningitis, as well as other peripheral vascular diseases, such as diabetes, hypertension, artheriosclerosis. Also included are methods of treatment using APC in combination with a co-factor, such as Protein S.

Methods of treating a subject having a condition characterized by at least one of neurodegeneration and neuroinflammation are provided. Methods of reducing astrogliosis in a subject having a condition characterized by increased astrogliosis are also provided. Methods of providing neuroprotection to a subject in need thereof are also provided.

Disclosed herein is a rodent and human behavioral test for evaluating visual dysfunctions associated with the retinal changes in Alzheimer disease progression. In one example, the inventors developed a maze that tests rodent's ability to identify (1) specific contrasts, (2) specific colors, (3) certain items in the visual field, and (4) other ‘non-typical’ peripheral and night vision functions associated with AD. For instance, the inventors developed a maze the tests the rodents ability to avoid certain colors or contrasts gradients. The maze may include certain rooms with specific visual markers (e.g., colors, contrasts, objects or other visual features) that also contain shock plates.

The invention discloses an intracranial stimulation and recording system. The intracranial stimulation and recording system comprises a flexible optical fibre, a laser and a flexible deep brain electrode; the flexible optical fibre is connected with the laser; and the flexible deep brain electrode is fixed to the flexible optical fibre through a clamp. Correspondingly, the invention further discloses a method for preparing the intracranial stimulation and recording system. According to the invention, the flexible deep brain electrode is attached to the surface of the flexible optical fibre; the laser serves as a light source, so that the functions of optical pulse nerve stimulation and nerve electrophysiological signal acquisition can be integrated; meanwhile, optogenetic excitation and inhibition are achieved; damage to brain tissues due to heating of an LED chip when the LED chip serves as the light source can be avoided; silk protein is adopted as main materials of a substrate layer, an insulating layer and a packaging layer of the flexible deep brain electrode; in combination with a flexible optical fibre material, the mechanical compliance of an implanted device to brain tissues can be greatly improved; therefore, neuroinflammation caused by long-term in-vivo stimulation and recording after the device is implanted is reduced; and long-term in-vivo stimulation and recordingare achieved.

The invention discloses a GSK-3beta/ChE double inhibitor with the structural formula shown as formula (I), or pharmaceutically acceptable salts and solvates of formula (I). The chemical small molecules involved in the invention can effectively inhibit the enzyme activity of GSK-3 beta, AChE and BChE, have the effects of improving cognition, reducing tau protein phosphorylation and reducing neuroinflammation, and have important application value in the preparation of drugs for preventing or treating Alzheimer's disease.

The invention discloses a flexible brain electrode with electrochemistry and electrophysiology detection functions and a preparation method of the flexible brain electrode. The flexible brain electrode comprises a first electrode, a first silk protein layer, a metal wiring layer, a second silk protein layer, a second electrode and a third silk protein layer which are sequentially arranged, whereinthe first electrode is used for carrying out electrochemistry detection, the second electrode is used for carrying out electrophysiology detection, and the first electrode and the second electrode are respectively located on two opposite surfaces of the flexible brain electrode; and the metal wiring layer is located between the first electrode and the second electrode, the first silk protein layer is arranged between the metal wiring layer and the first electrode, the second silk protein layer is arranged between the metal wiring layer and the second electrode, and the third silk protein layer is located on the second silk protein layer. According to the flexible brain electrode, ''super-flexibility, high-resolution, high-integration-density and long-term in vivo'' nerve electrophysiology/neurotransmitter electrochemistry synchronous recording can be realized.

In its many embodiments, the present invention provides provides certain thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidone compounds, including compounds (or tautomers or a pharmaceutically acceptable salts thereof) having the structural Formula (III): wherein R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, and R⁹ are each selected independently and as defined herein. Pharmaceutical compositions comprising one or more such compounds, and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's Disease, are also disclosed.

A method for mitigating the effects of traumatic brain injury in an individual comprising is disclosed. The method includes administering an amount of a composition prior to a period wherein the traumatic brain injury is expected to occur, wherein the composition is comprised of: 300 mg and 500 milligrams (mg) of Docosahexaenoic acid (DHA), 50 mg/kg to 400 mg/kg (milligrams of composition per kilogram of body weight of the individual) of curcumin, and 10 mg to 100 mg of resveratrol. In some embodiments, the composition may include 350 mg of DHA, 150 mg/kg of curcumin and 30 mg of resveratrol. In additional embodiments, the composition may further include α-linoleic acid of an amount within the range of, for example, 1-2 g. The composition may be administered to the individual within a predetermined amount of time prior to a period wherein the traumatic brain injury is expected to occur.

The invention provides application of hydrogen sulfide modified mesenchymal stem cells (MSCs) extracellular vesicles (EVs) serving as a miRNA delivery vector to hypoxic-ischemic brain damage (HIBD). According to the application, it is discovered and proved by first research that the curative effect of miR-7b-5p in HIBD can be effectively improved by adopting H2S to pretreat MSCs EVs. Specifically,through research, it is found that H2S-EVs can be adopted to serve as a natural excellent vector of miR-7b-5p, and exerts the better neuroprotection effect in HIBD; and meanwhile, by inhibiting expression of a target gene FOS, HI-induced brain damage and related neuroinflammation can be effectively relieved.

The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A/D2 receptor ligand, e.g. lumateperone.

Methods of treating the effects of disruption of normal blood flow in the CNS in an individual subject in need thereof are provided according to aspects of the present invention which include administering a therapeutically effective dose of exogenous NeuroD1 to an area where normal blood flow has been disrupted. Compositions are provided including 1) a recombinant adeno-associated adenovirus expression vector comprising a glial cell specific promoter operably linked to a nucleic acid encoding a site-specific recombinase and 2) a recombinant adeno-associated adenovirus expression vector comprising a ubiquitous promoter operably linked to a nucleic acid encoding NeuroD1, wherein the nucleic acid encoding NeuroD1 is inverted and flanked by two sets of site-specific recombinase recognition sites such that action of the recombinase irreversibly inverts the nucleic acid encoding NeuroD1 such that NeuroD1 is expressed in a mammalian cell.

Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.

The invention belongs to the technical field of drugs for treating degenerative diseases, and relates to application of dimethyl itaconate in preparation of a medicine for treating and/or preventing neurodegenerative diseases. Experiments prove that the dimethyl itaconate can alleviate the decline of learning and memory ability and the damage of synaptic ultrastructures, and reduce neuroinflammation.

Disclosed herein include methods, compositions, and kits suitable for use in preventing and treating Alzheimer's disease. In some embodiments, methods of delaying or reducing the likelihood of onset of Alzheimer's disease are provided. The method can comprise administering to a subject in need thereof a composition comprising a neurokinin 1 receptor (NK1R) antagonist (e.g., aprepitant).

A method for mitigating the effects of traumatic brain injury in an individual comprising is disclosed. The method includes administering an amount of a composition prior to a period wherein the traumatic brain injury is expected to occur, wherein the composition is comprised of: 300 mg and 500 milligrams (mg) of Docosahexaenoic acid (DHA), 50 mg/kg to 400 mg/kg (milligrams of composition per kilogram of body weight of the individual) of curcumin, and 10 mg to 100 mg of resveratrol. In some embodiments, the composition may include 350 mg of DHA, 150 mg/kg of curcumin and 30 mg of resveratrol, In additional embodiments, the composition may further include α-linoleic acid of an amount within the range of, for example, 1-2 g. The composition may be administered to the individual within a predetermined amount of time prior to a period wherein the traumatic brain injury is expected to occur.

The invention belongs to the field of medicine preparation, and relates to a new medicinal use of nafamostat mesilate. A series of integral animal experiments and cell experiments show that the nafamostat mesilate can effectively reduce neuroinflammation, prevents cerebral thrombosis after cerebral injury, reduces neuron injury, improves cognitive impairment after the cerebral injury and recovers the damaged blood cerebral barrier functions in order to prevent and treat the generation and development of cerebrovascular pathology and other neurological diseases.

A compound has formula (I), where R is selected from a methyl group or an ethyl group:

The compound can be hydroxy acid forms thereof, the pharmaceutically acceptable salts of the hydroxy acids and pharmaceutically acceptable prodrugs and solvates of the compounds and of the hydroxy acid forms thereof. The compounds can be used in the prevention or treatment of: neurodegenerative or neurological diseases, cognitive impairment, diseases with impaired APP metabolism, inflammation or inflammatory processes, or epilepsy, epileptic seizures and convulsions.

The invention discloses application of an aqueous extract prepared by a traditional Chinese medicine prescription in preparing a medicine for treating senile dementia. Multiple traditional Chinese medicine extracts are combined as a medicine for treating Alzheimer's diseases, animal experiment verifies that the prepared medicine composition has a treatment effect equivalent to that of donepezil and is capable of preventing and treating learning and memory failure, relieving neuron damage, repressing reduction of the number of neurons, and alleviating neuroinflammation and apoptosis reactions in attack of the Alzheimer's diseases. The aqueous extract is wide in material sources, easy to obtain, simple and feasible in medicine preparation and good in treatment effect.